title: Time-frequency analysis of transient-evoked otoacoustic emissions in children exposed to carboplatin chemotherapy.
abstract: The aims of this study were to characterize and quantify time-frequency changes in transient-evoked otoacoustic emissions (TEOAEs) recorded in children diagnosed with retinoblastoma who were receiving carboplatin chemotherapy. A signal processing technique, the wavelet transform (WT), was used to analyze TEOAE waveforms in narrow-band frequency components. Ten children (aged 3-72 months) diagnosed with unilateral or bilateral retinoblastoma were enrolled in the study. TEOAEs were acquired from the children with linear sequences of 70 dB peak equivalent SPL clicks. After WT analysis, TEOAE energy, latency and normalized energy in the narrow-band frequency components were compared before and during carboplatin chemotherapy treatment (average dose 1693 mg/m2). On a group basis, no significant differences (p>0.05) in the TEOAE energy, latency or normalized energy before and after carboplatin treatment were observed. There were decreases in normalized energy on an individual basis in 10 out of 18 ears in the sample. Exposure to carboplatin chemotherapy did not cause significant changes in TEOAE energy, latency and normalized energy during treatment. However, long-term monitoring of hearing with measurements of TEOAEs is warranted, given the risks of delayed hearing loss in some children receiving carboplatin chemotherapy.
authors.affiliation: Hearing Science Laboratory, School of Communication Sciences and Disorders, The University of Memphis, and St. Jude Children's Research Hospital, Memphis, TN 38105, USA. sbhagat@memphis.edu
authors.forename: Shaum
authors.initials: S
authors.lastname: Bhagat
authors.forename: Johnnie
authors.initials: J
authors.lastname: Bass
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Qaddoumi
authors.forename: Rachel
authors.initials: R
authors.lastname: Brennan
authors.forename: Matthew
authors.initials: M
authors.lastname: Wilson
authors.forename: Jianrong
authors.initials: J
authors.lastname: Wu
authors.forename: Carlos-Rodriguez
authors.initials: CR
authors.lastname: Galindo
authors.forename: Alessia
authors.initials: A
authors.lastname: Paglialonga
authors.forename: Gabriella
authors.initials: G
authors.lastname: Tognola
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold / Q000187:drug effects; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D016903:Drug Monitoring / Q000379:methods; D005260:Female; D034381:Hearing Loss / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D008297:Male; D017084:Otoacoustic Emissions, Spontaneous / Q000187:drug effects*; D011930:Reaction Time / Q000187:drug effects; D019572:Retinal Neoplasms / Q000188:drug therapy*; D012175:Retinoblastoma / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin